Centogene N.V.
Centogene N.V. (CNTG) Stock Overview
Explore Centogene N.V.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
9.4M
P/E Ratio
-0.22
EPS (TTM)
$-1.39
ROE
3.98%
CNTG Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Centogene N.V. (CNTG) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.08.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.22 and a market capitalization of 9.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Kim Stratton
384
Am Strande 7, Rostock
2019